Nanobody Quantum Dot Immunochromatography for CSFV Strain Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for distinguishing classical swine fever virus (CSFV) E2 subunit vaccine strains from wild strains are complex, time-consuming, and lack sensitivity, particularly in field applications.
Innovation Solution
Development of a nanobody CSFV-E0-Nb1 against the CSFV E0 protein, combined with quantum dot immunochromatography, to create an immunochromatographic test strip that rapidly and efficiently differentiates between antibodies produced by vaccine strains and wild strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional ELISA or PCR methods are used for CSFV detection, then detection accuracy is improved, but device complexity and operation difficulty increase
Solution Approach 1:
The patent extracts the core detection function from complex laboratory equipment and implements it in a simplified immunochromatographic test card format. The test card integrates sample application, antibody-antigen reaction, and result visualization into a single portable device, eliminating the need for complex ELISA or PCR equipment while maintaining detection capability through visual readout of test lines.
Solution Approach 2:
The patent introduces specific antibodies (anti-E2 and anti-E0) as intermediaries to mediate between the virus antigens and the detection system. These antibodies serve as recognition elements that bind specifically to viral antigens, enabling selective detection and differentiation of CSFV strains through the formation of visible immune complexes at test lines.
2Measurement precision
If traditional ELISA or PCR methods are used for CSFV detection, then detection accuracy is improved, but detection time increases
Solution Approach 1:
The patent incorporates pre-coated capture antibodies and detection antibodies onto the test card membrane during manufacturing. These antibodies are prepared in advance and immobilized at specific positions, so that when a sample is applied, the detection reaction can proceed immediately without requiring preliminary preparation steps in the laboratory.
Solution Approach 2:
The immunochromatographic method skips the multiple washing, incubation, and signal amplification steps required in traditional ELISA and PCR procedures. The sample flows through the membrane in a single continuous process, allowing antibody-antigen interactions to occur rapidly as the sample migrates, with results visible within minutes rather than hours.
3Measurement precision
If quantum dot immunochromatography is used, then detection sensitivity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes quantum dots with specific size parameters (2-5 nm diameter) and surface properties to achieve enhanced fluorescence intensity and photostability. By controlling the size and composition parameters of the quantum dots, the detection sensitivity is improved through increased signal intensity, while the standardized synthesis protocols maintain manufacturing feasibility.
Solution Approach 2:
The patent employs composite structures combining quantum dot nanoparticles with antibody molecules to create fluorescently labeled immunoprobes. This composite material integrates the high fluorescence quantum yield of quantum dots with the specific antigen-binding capability of antibodies, achieving both high sensitivity and ease of use in the immunochromatographic assay.
4Measurement precision
If quantum dot immunochromatography is used, then detection sensitivity is improved, but production cost increases
Solution Approach 1:
The patent employs disposable immunochromatographic test cards that integrate quantum dot-labeled antibodies at low concentrations. Each test card is designed for single use, eliminating the need for expensive equipment and complex reagent preparations. The quantum dots are used in small quantities per test, and the overall system cost is reduced by eliminating laboratory instrumentation and trained personnel requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The test strip provides timely, efficient, and rapid on-site differentiation of infections, offering higher sensitivity and specificity compared to traditional methods, and reduces production costs, making it suitable for market application.
Implementation Method 1
a nanobody CSFV-E0-Nb1 against CSFV E0 protein
Implementation Method 2
Quantum dots have a series of unique and excellent optical properties, including: i) quantum dots are more stable than organic fluorescent molecules and are not prone to photobleaching; ii) they have a wide fluorescence absorption spectrum... iv) quantum dots exhibit high fluorescence intensity and high quantum yield (>20%)
Implementation Method 3
Based on the nanobody and quantum dot immunochromatography, an immunochromatographic test strip is developed
Data Source
AI summary
A nanobody classical swine fever virus (CSFV)-E0-Nb1 against a CSFV E0 protein, and an encoding gene and use thereof are provided, belonging to the technical field of biological detection. The nanobody CSFV-E0-Nb1 has an amino acid sequence shown in SEQ ID NO: 1 and can be expressed using an expression system. The nanobody is coupled with a quantum dot to obtain an immunochromatographic test strip for distinguishing antibodies against a CSFV E2 subunit vaccine strain from those of a wild strain infected on site, and there is a simple production process of the test strip. The immunochromatographic test strip can differentiate and diagnose the antibodies against the CSFV E2 subunit vaccine strain and the wild strain, and has the advantages of rapid, convenient, and instant detection, thus providing a new method for the detection of classical swine fever (CSF) purification.